Your browser is no longer supported. Please, upgrade your browser.
ILMN Illumina, Inc. daily Stock Chart
Illumina, Inc.
IndexS&P 500 P/E41.28 EPS (ttm)2.99 Insider Own0.70% Shs Outstand146.69M Perf Week-3.32%
Market Cap18.11B Forward P/E33.19 EPS next Y3.72 Insider Trans-9.55% Shs Float145.18M Perf Month-10.33%
Income443.40M PEG2.84 EPS next Q0.81 Inst Own94.80% Short Float3.03% Perf Quarter-25.10%
Sales2.37B P/S7.64 EPS this Y30.50% Inst Trans-2.53% Short Ratio3.02 Perf Half Y-12.81%
Book/sh15.27 P/B8.09 EPS next Y11.95% ROA11.30% Target Price144.47 Perf Year-30.96%
Cash/sh10.47 P/C11.79 EPS next 5Y14.51% ROE21.80% 52W Range119.37 - 196.47 Perf YTD-35.67%
Dividend- P/FCF42.92 EPS past 5Y28.90% ROI16.60% 52W High-37.15% Beta1.19
Dividend %- Quick Ratio3.10 Sales past 5Y19.70% Gross Margin69.90% 52W Low3.44% ATR4.30
Employees4600 Current Ratio3.60 Sales Q/Q10.30% Oper. Margin24.80% RSI (14)33.08 Volatility2.76% 3.34%
OptionableYes Debt/Eq0.47 EPS Q/Q10.40% Profit Margin18.70% Rel Volume0.76 Prev Close122.02
ShortableYes LT Debt/Eq0.46 EarningsNov 01 AMC Payout0.00% Avg Volume1.45M Price123.48
Recom2.90 SMA20-7.26% SMA50-14.58% SMA200-18.84% Volume1,100,485 Change1.20%
Dec-07-16Reiterated Morgan Stanley Underweight $115 → $100
Nov-10-16Resumed Leerink Partners Mkt Perform
Nov-02-16Downgrade First Analysis Sec Equal-Weight → Underweight $130 → $116
Oct-11-16Reiterated Cantor Fitzgerald Hold $165 → $155
Oct-11-16Reiterated Canaccord Genuity Hold $165 → $136
Oct-11-16Downgrade Citigroup Buy → Neutral
Aug-22-16Downgrade CL King Buy → Neutral
Jul-27-16Reiterated Mizuho Neutral $138 → $148
Jul-05-16Downgrade Morgan Stanley Equal-Weight → Underweight $130 → $110
Jun-22-16Initiated CL King Buy
May-04-16Reiterated Stifel Buy $215 → $160
May-04-16Reiterated Mizuho Neutral $150 → $138
May-04-16Reiterated Canaccord Genuity Hold $160 → $140
May-03-16Reiterated UBS Buy $210 → $180
May-03-16Reiterated Morgan Stanley Overweight $140 → $130
Apr-19-16Downgrade Cantor Fitzgerald Buy → Hold
Apr-19-16Downgrade BofA/Merrill Buy → Neutral
Feb-04-16Downgrade Canaccord Genuity Buy → Hold $205 → $160
Feb-03-16Reiterated Deutsche Bank Hold $178 → $160
Jan-07-16Reiterated Barclays Equal Weight $170 → $175
Dec-07-16 05:07PM  Are there buying opportunities in health care?
04:12PM  ILLUMINA INC Files SEC form 8-K, Change in Directors or Principal Officers
09:22AM  The Worst American Stocks of 2016 at Motley Fool
06:30AM  Illumina Extends Management Team, Appoints Sam A. Samad as Senior Vice President and Chief Financial Officer Business Wire
Dec-03-16 11:19AM  Can Illumina Regain Its Mojo? at Motley Fool
Dec-01-16 04:21PM  OraSure Stock Sets Up For Buy Point On Hep C Contract, Helix Win
09:33AM  3 Ways Pacific Biosciences of California Can Rebound in 2017 at Motley Fool
09:00AM  Illumina Launches iHope Program to Identify Causes of Undiagnosed Genetic Diseases in Children Business Wire
Nov-29-16 04:56PM  ILLUMINA INC Files SEC form 8-K, Change in Directors or Principal Officers
08:32AM  3 Biotech Stocks to Buy on Sale at Motley Fool
Nov-28-16 06:30AM  Illumina to Webcast Live Presentation at the Citi Global Healthcare Conference Business Wire
Nov-26-16 03:43PM  Illumina, Inc. (ILMN): Hedge Fund Ownership Half What It Was Last Year at Insider Monkey
Nov-22-16 09:08AM  The Market In 5 Minutes: Dow, S&P 500 Trading At All-Time Highs
06:02AM  Attention, Biotech Investors: Black Friday Is Already Here at Motley Fool
Nov-18-16 01:38PM  Calls look for rebound in Illumina
01:14PM  ETFs with exposure to Illumina, Inc. : November 18, 2016
12:50PM  Cerner Health Conference: Genomics is the 'next great frontier' at
11:45AM  Stock market edges lower as dollar strength continues at MarketWatch
Nov-15-16 01:04PM  ILLUMINA INC Financials
Nov-10-16 09:00AM  Illumina and Mayo Clinic Form Bioinformatics Relationship to Advance Genetic Disorder Testing Business Wire
Nov-09-16 08:09AM  Is Illumina Inc. a Buffett Stock? at Motley Fool
07:57AM  Illumina Launches TruSight Tumor 170 for Tumor Profiling
Nov-08-16 06:04AM  ILLUMINA INC Files SEC form 10-Q, Quarterly Report
Nov-07-16 09:00AM  Illumina Launches TruSight Tumor 170 Business Wire
Nov-05-16 07:12AM  Illumina Inc. Is Floundering: Here's What Management Had to Say at Motley Fool
Nov-04-16 12:47PM  ETFs with exposure to Illumina, Inc. : November 4, 2016
Nov-03-16 04:12PM  Qiagen NV Jumps After Beating Its Earnings Guidance at Motley Fool
10:42AM  New Strong Sell Stocks for November 3rd
09:27AM  Illumina, Inc. :ILMN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016
Nov-02-16 10:45AM  Illumina Inc. Q3 Weighed Down by Sluggish High-Throughput System Sales at Motley Fool
08:53AM  Illumina (ILMN) Beats Q3 Earnings, Revenues Miss the Mark
06:56AM  Illumina downgraded by First Analysis Sec
Nov-01-16 05:03PM  ILLUMINA INC Files SEC form 8-K, Change in Directors or Principal Officers
05:00PM  Illumina Inc Earnings Call scheduled for 5:00 pm ET today
04:21PM  Illumina beats 3Q profit forecasts
04:05PM  Illumina Reports Full Financial Results for Third Quarter of Fiscal Year 2016 Business Wire
07:07AM  Q3 2016 Illumina Inc Earnings Release - After Market Close
Oct-31-16 09:21AM  Genetic Stocks to Watch for Earnings on Nov 1: GILD & More
Oct-29-16 12:01AM  [$$] These Top Stockpickers Have Stumbled at
Oct-28-16 10:14PM  INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Illumina Inc. and Advises Investors with Losses to Contact the Firm Business Wire
05:46PM  Lifshitz & Miller Law Firm Announces Investigation of Alnylam Pharmaceuticals, Inc., Chesapeake Energy Corporation, Cognizant Technology Solutions Corporation, Fenix Parts, Inc., Genworth Financial, Inc., Illumina Inc., ProNAi Therapeutics, PR Newswire
09:21AM  Should You Sell Illumina Stock?
Oct-27-16 07:02AM  Illumina, Inc. in 3 Charts at Motley Fool
Oct-26-16 09:30AM  Vail Resorts, Illumina, Coca-Cola, Boston Scientific and Equifax highlighted as Zacks Bull and Bear of the Day
Oct-25-16 01:29PM  Baron Funds Comments on Illumina Inc.
12:20PM  Baron Opportunity Fund 3rd Quarter Commentary
Oct-24-16 04:05PM  German Court Issues Preliminary Injunction Against amedes Fetalis® Test for Infringement of Non-Invasive Prenatal Screening Patent Business Wire
08:15AM  Illumina (ILMN) Q3 Earnings: Disappointment in the Cards?
Oct-23-16 01:26PM  No Cure Yet for Breast Cancer, but 3 Big Advances in 2016 at Motley Fool
Oct-21-16 09:52PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Illumina Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
05:33PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Illumina Inc. Business Wire
04:12PM  Baron Funds Comments on Illumina
11:08AM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Illumina Inc. and Advises Investors with Losses to Contact the Firm Business Wire
10:15AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Illumina Inc. (ILMN) PR Newswire
Oct-20-16 05:29PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Illumina Inc. and Advises Investors with Losses to Contact the Firm Business Wire
04:12PM  INVESTOR ALERT: Investigation of Illumina Inc. Announced by Law Offices of Howard G. Smith Business Wire
09:00AM  Illumina Contributes to ClinVar Database Business Wire
Oct-19-16 01:08PM  The Holy GRAIL of Healthcare? Illumina Eyes Up A Potential $200 Billion Market at Motley Fool
12:56PM  What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers
10:15AM  New Strong Sell Stocks for October 19th
Oct-17-16 01:20PM  George Church-founded gene sequencing firm Veritas Genetics raises $30M at
09:50AM  Buy on the Dip? 3 Reasons to Buy Illumina and Never Sell at Motley Fool
Oct-15-16 07:04AM  These 3 Stocks Are Up Over 500% Over the Last 10 Years at Motley Fool
Oct-14-16 10:50AM  ETFs with exposure to Illumina, Inc. : October 14, 2016
Oct-13-16 05:02PM  Does a Clinton Victory Scare the Biotech Sector? (AMGN, ILMN) at Investopedia
10:41AM  Illumina Hurt By Lower Projected 3Q Sales (ILMN) at Investopedia
Oct-12-16 04:30PM  3 Warning Signs from Illumina, Inc.'s Q3 Preview at Motley Fool
04:06PM  Earnings Season On Deck: How Has Q3 Guidance Looked So Far?
04:01PM  Stocks Closed Mixed After Fed Minutes; Humana, HMOs Dive
03:45PM  Biotech Movers And Shakers: Vericel Corp (VCEL) and Illumina, Inc. (ILMN) at Insider Monkey
03:12PM  The market gets its first big genetically designed disaster at CNBC
12:10PM  The politics of health care
10:10AM  Company News for October 12, 2016
08:50AM  Illumina, Inc. breached its 50 day moving average in a Bearish Manner : ILMN-US : October 12, 2016
06:58AM  Alcoa stock slammed by earnings disaster as season gets off on the back foot at MarketWatch
02:02AM  GLOBAL MARKETS-Asia shares slip as US earnings disappoint, dollar gains Reuters
Oct-11-16 06:03PM  Indexes Tank But Apple, Twitter Stay Afloat; Lumentum, Illumina Dive -24.81%
05:15PM  Biotech bloodbath
04:59PM  Biotech Stocks Smacked For Biggest Decline in 3 1/2 Months at The Wall Street Journal
04:45PM  Illumina Leads Healthcare Selloff, Abbott and Zimmer Also Fall
04:42PM  Rent-A-Center, St. Jude Medical fall; Twilio, Tyson gain
04:40PM  GLOBAL MARKETS-Wall Street stocks slide, dollar hits 8-month high Reuters
04:31PM  US STOCKS-Wall St sells off on weak earnings, election fears
04:31PM  Supernus Stock Reverses Downward Despite Good ADHD Drug Trial
04:15PM  Illumina Stock Crashes On Troubling Outlook, Sales Miss
03:11PM  US STOCKS-Wall St sells off amid weak earnings, election jitters
02:53PM  GLOBAL MARKETS-Wall Street slides, dollar hits 8-month high Reuters
01:50PM  Illumina's Unfortunate Sequencing at Bloomberg
01:43PM  [$$] Illumina shares slide on sales 'credibility gap' at Financial Times
01:39PM  Illumina sinks on Q3 sales
01:38PM  Stocks Down, Nasdaq Gets Near 50-Day Line; Medicals Smacked, Apple Still Firm
12:54PM  Why Illumina, Inc. Is Plunging Today at Motley Fool
11:22AM  Dow Drops 173 Points As Alcoa, Illumina, Oil Weigh On Stocks at
11:01AM  Illumina Plunges 25% On Lower Q3 Sales; Janney Cuts To Sell at
10:59AM  Illumina's Pain Infects Biotech ETFs at
10:57AM  Illumina stock craters 26% after preliminary warning of revenue miss at MarketWatch
10:29AM  Illumina (ILMN) Stock Tanks After Lower Q3 Outlook, Downgrades
10:25AM  Alcoa Kicks Off Earnings Season With Miss; Apple Jumps On Galaxy Halt
10:19AM  Illumina shares plummet 25 percent after cutting revenue forecast at CNBC
10:15AM  Illumina is crashing after giving investors terrible news about its revenue
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array. In addition, the company provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and non-invasive prenatal testing services. It serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as through life-science distributors. It has a collaboration agreement With MolecularMD Corporation for drug-diagnostic co-development with biopharma drug programs. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OSTADAN OMEADEVP Ops, Products, StrategyDec 01Sale133.303,000399,90051,492Dec 05 06:41 PM
BRADBURY DANIELDirectorNov 14Option Exercise71.0960042,65417,065Nov 15 06:14 PM
BRADBURY DANIELDirectorNov 14Sale136.3460081,80316,465Nov 15 06:14 PM
BRADBURY DANIELDirectorOct 07Option Exercise71.0960042,65417,065Oct 11 08:35 PM
BRADBURY DANIELDirectorOct 07Sale184.36600110,61316,465Oct 11 08:35 PM
Dadswell CharlesSr VP & General CounselOct 04Sale182.3811621,15639,900Oct 06 05:32 PM
EPSTEIN ROBERT SDirectorSep 20Sale174.2930052,2876,924Sep 21 06:56 PM
Stapley MarcEVP & Chief Administrative OfcSep 15Sale172.871,270219,54332,746Sep 16 08:07 PM
BRADBURY DANIELDirectorSep 14Option Exercise71.0960042,65417,065Sep 16 07:58 PM
BRADBURY DANIELDirectorSep 14Sale171.25600102,74816,465Sep 16 07:58 PM
Dadswell CharlesSr VP & General CounselSep 06Sale168.0111619,48940,016Sep 08 07:58 PM
FLATLEY JAY TDirectorAug 23Option Exercise36.3020,000726,000508,061Aug 25 08:43 PM
FLATLEY JAY TDirectorAug 23Sale172.9920,0003,459,877488,061Aug 25 08:43 PM
EPSTEIN ROBERT SDirectorAug 22Sale170.2730051,0817,224Aug 24 07:52 PM
EPSTEIN ROBERT SDirectorAug 22Sale170.2730051,0817,224Aug 23 08:19 PM
BRADBURY DANIELDirectorAug 17Option Exercise71.0960042,65417,065Aug 18 08:31 PM
BRADBURY DANIELDirectorAug 17Sale168.42600101,05316,465Aug 18 08:31 PM
FLATLEY JAY TDirectorAug 15Option Exercise36.3010,000363,000498,061Aug 16 06:56 PM
FLATLEY JAY TDirectorAug 15Sale170.0010,0001,700,000488,061Aug 16 06:56 PM
WHITFIELD ROY ADirectorAug 12Option Exercise42.824,000171,2806,853Aug 15 06:03 PM
WHITFIELD ROY ADirectorAug 12Sale167.224,000668,8802,853Aug 15 06:03 PM
FLATLEY JAY TDirectorAug 09Option Exercise36.3010,000363,000498,061Aug 10 09:40 PM
FLATLEY JAY TDirectorAug 09Sale165.9710,0001,659,650488,061Aug 10 09:40 PM
Dadswell CharlesSr VP & General CounselAug 04Sale164.6311619,09740,132Aug 08 06:36 PM
FLATLEY JAY TDirectorAug 01Option Exercise36.3010,000363,000498,061Aug 02 07:27 PM
FLATLEY JAY TDirectorAug 01Sale170.0010,0001,700,000488,061Aug 02 07:27 PM
Dadswell CharlesSr VP & General CounselJul 27Sale155.008,6321,337,96040,248Jul 28 07:44 PM
FLATLEY JAY TDirectorJul 26Option Exercise36.3010,000363,000498,061Jul 28 07:39 PM
FLATLEY JAY TDirectorJul 26Sale150.0010,0001,500,000488,061Jul 28 07:39 PM
EPSTEIN ROBERT SDirectorJul 20Sale150.0030045,0007,524Jul 20 08:08 PM
FLATLEY JAY TDirectorJul 18Option Exercise36.3010,000363,000498,061Jul 20 08:06 PM
EPSTEIN ROBERT SDirectorJul 18Sale150.00900135,0007,824Jul 20 08:08 PM
FLATLEY JAY TDirectorJul 18Sale150.0010,0001,500,010488,061Jul 20 08:06 PM
BOWMAN A BLAINEDirectorJul 14Option Exercise42.825,000214,10020,704Jul 15 06:53 PM
BOWMAN A BLAINEDirectorJul 14Sale147.145,000735,70515,704Jul 15 06:53 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerJul 11Sale141.89716101,59318,976Jul 12 07:47 PM
BOWMAN A BLAINEDirectorJun 16Option Exercise42.825,000214,10020,704Jun 17 07:53 PM
BOWMAN A BLAINEDirectorJun 16Sale135.085,000675,38815,704Jun 17 07:53 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerJun 15Sale137.902,141295,24219,692Jun 15 06:47 PM
WHITFIELD ROY ADirectorJun 13Option Exercise42.822,00085,6406,653Jun 15 06:34 PM
WHITFIELD ROY ADirectorJun 13Sale140.443,800533,6722,853Jun 15 06:34 PM
EASTHAM KARINDirectorJun 01Option Exercise36.295,000181,45017,424Jun 03 07:28 PM
EASTHAM KARINDirectorJun 01Sale145.355,000726,75012,424Jun 03 07:28 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMay 25Sale144.732,141309,86721,833May 26 07:44 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMay 17Sale140.842,141301,53223,974May 19 06:56 PM
BOWMAN A BLAINEDirectorMay 12Option Exercise36.295,000181,45018,615May 13 06:03 PM
BOWMAN A BLAINEDirectorMay 12Sale137.115,000685,53513,615May 13 06:03 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 27Sale138.462,141296,44626,115Apr 28 06:34 PM
Bianchi Paul LSr. VP, Human ResourcesApr 18Sale175.001,884329,70065,660Apr 20 05:33 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 18Sale176.012,141376,83528,256Apr 20 05:57 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 13Option Exercise37.0412,500463,00042,897Apr 14 06:43 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 13Sale175.0012,5002,187,50030,397Apr 14 06:43 PM
WHITFIELD ROY ADirectorApr 12Option Exercise42.824,000171,2805,800Apr 14 06:21 PM
FLATLEY JAY TChief Executive OfficerApr 12Option Exercise36.3020,000726,000508,061Apr 14 06:42 PM
FLATLEY JAY TChief Executive OfficerApr 12Sale170.0520,0003,401,014488,061Apr 14 06:42 PM
WHITFIELD ROY ADirectorApr 12Sale170.004,000680,0001,800Apr 14 06:21 PM
WALT DAVID RDirectorApr 07Option Exercise13.304,00053,200635,840Apr 11 05:58 PM
WALT DAVID RDirectorApr 07Sale168.904,000675,596631,840Apr 11 05:58 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerApr 05Sale166.072,141355,54630,397Apr 06 05:29 PM
Dadswell CharlesSr VP & General CounselApr 04Sale167.818,3821,406,60449,859Apr 06 05:19 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMar 23Sale155.052,141331,95732,538Mar 23 05:41 PM
FLATLEY JAY TChief Executive OfficerMar 22Option Exercise36.3010,000363,000498,061Mar 23 05:39 PM
FLATLEY JAY TChief Executive OfficerMar 22Sale154.1810,0001,541,759488,061Mar 23 05:39 PM
BRADBURY DANIELDirectorMar 21Option Exercise44.511,20053,41215,576Mar 22 02:51 PM
BRADBURY DANIELDirectorMar 21Sale155.631,200186,75614,376Mar 22 02:51 PM
Naclerio NicholasSr VP, Corporate DevelopmentMar 21Sale154.254,520697,21030,020Mar 22 02:48 PM
BOWMAN A BLAINEDirectorMar 17Option Exercise36.295,000181,45018,615Mar 18 08:49 PM
BOWMAN A BLAINEDirectorMar 17Sale145.245,000726,19213,615Mar 18 08:49 PM
WALT DAVID RDirectorMar 15Option Exercise13.304,00053,200635,840Mar 16 09:16 PM
WALT DAVID RDirectorMar 15Sale149.994,000599,961631,840Mar 16 09:16 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMar 14Sale155.915,892918,61834,679Mar 15 07:42 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 09Sale150.32871130,92955,189Mar 11 11:43 AM
FLATLEY JAY TChief Executive OfficerMar 08Option Exercise36.3010,000363,000500,915Mar 09 06:45 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 08Sale156.094,516704,90256,060Mar 09 06:52 PM
FLATLEY JAY TChief Executive OfficerMar 08Sale154.4910,0001,544,864490,915Mar 09 06:45 PM
Dadswell CharlesSr VP & General CounselMar 08Sale155.648,2661,286,51758,241Mar 09 06:38 PM
Dadswell CharlesSr VP & General CounselMar 07Sale155.0011617,98066,507Mar 09 06:38 PM
Stapley MarcEVP & Chief Administrative OfcMar 03Option Exercise0.0024,000040,801Mar 07 08:11 PM
FLATLEY JAY TChief Executive OfficerMar 03Option Exercise0.0083,8300514,614Mar 07 08:09 PM
deSouza Francis APresidentMar 03Option Exercise0.0049,2190118,880Mar 07 08:07 PM
Ronaghi MostafaSr VP & CTOMar 03Option Exercise0.0020,063062,763Mar 07 08:05 PM
ORPIN TRISTANEVP Clinical GenomicsMar 03Option Exercise0.0024,0000125,797Mar 07 08:02 PM
Naclerio NicholasSr VP, Corporate DevelopmentMar 03Option Exercise0.0020,063040,866Mar 07 08:00 PM
HENRY CHRISTIAN OEVP & Chief Commercial OfficerMar 03Option Exercise0.0024,000047,536Mar 07 07:58 PM
Dadswell CharlesSr VP & General CounselMar 03Option Exercise0.0033,750075,325Mar 07 07:56 PM
Bouchard MichelChief Accounting OfficerMar 03Option Exercise0.008,250023,746Mar 07 08:14 PM
FLATLEY JAY TChief Executive OfficerFeb 23Option Exercise36.3010,000363,000440,784Feb 25 07:05 PM
FLATLEY JAY TChief Executive OfficerFeb 23Sale152.4910,0001,524,850430,784Feb 25 07:05 PM
BRADBURY DANIELDirectorFeb 17Option Exercise44.511,70075,66716,076Feb 19 11:27 AM
BRADBURY DANIELDirectorFeb 17Sale154.741,700263,05114,376Feb 19 11:27 AM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 01Sale156.731,108173,65746,476Feb 03 06:58 PM
FLATLEY JAY TChief Executive OfficerJan 26Option Exercise36.3020,000726,000453,423Jan 28 06:09 PM
FLATLEY JAY TChief Executive OfficerJan 26Sale171.7020,0003,434,082433,423Jan 28 06:09 PM
BRADBURY DANIELDirectorJan 04Option Exercise44.511,70075,66716,076Jan 04 06:33 PM
BRADBURY DANIELDirectorJan 04Sale182.801,700310,75614,376Jan 04 06:33 PM
Dadswell CharlesSr VP & General CounselDec 28Sale188.6316831,69041,830Dec 30 02:36 PM
FLATLEY JAY TChief Executive OfficerDec 22Option Exercise31.3025,000782,550458,423Dec 24 10:54 AM
FLATLEY JAY TChief Executive OfficerDec 22Sale185.3825,0004,634,560433,423Dec 24 10:54 AM
WHITFIELD ROY ADirectorDec 14Option Exercise36.293,750136,08817,398Dec 15 05:40 PM
WHITFIELD ROY ADirectorDec 14Sale175.073,750656,51313,648Dec 15 05:40 PM